Zota Health Care Limited (ZOTA) Fair Value & Analysis
Healthcare · IN · Market cap ₹43.5B
Fair value as of: Jul 3, 2026
From 4 valuation models · updated today
Share price +17.9% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,043 – ₹1,687 · fair‑value band ₹622.84 – ₹4,703 · the ₹1,445 price screens below the ₹2,663 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Zota Health Care Limited (ZOTA) currently trades at ₹1,445, while our model-based Fair Value estimate is ₹2,663 — implying the stock looks roughly 84.3% undervalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Zota Health Care Limited generated revenue of ₹5.4B at a net margin of -13.7%. Revenue grew 67.7% year over year. It earns a return on equity of -16.1%. Net debt stands at ₹1.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers generic drugs, health supplements, over-the-counter products, wellness and ayurvedic products, and nutraceutical products. It provides various medicines for chronic ailments, such as diabetes, cardiac, and thyroid disorders. The company operates its retail stores under the DAVAINDIA name. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Zota Health Care Limited reported revenue of ₹5.4B in FY2026 versus ₹1.3B in FY2022, a compound +42.3%/yr. Reported net income was −₹739M in FY2026.
Is ZOTA fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zota Health Care Limited (ZOTA) undervalued?
What is the fair value of ZOTA?
What is the quality score of ZOTA?
What is the revenue of Zota Health Care Limited (ZOTA)?
What is the net profit margin of ZOTA?
Does Zota Health Care Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.